Clinical Outcomes of a Phase II, Multi-Institutional Cesium-131 Premanent Prostate Brachytherapy Trial

Cancer types prostate


B. Prestidge

April 29, 2007
Dr. Prestidge, from San Antonio, reported in 2007 on the ground-breaking 100-patient clinical study known as the “Cesium Monotherapy Trial.”They noted only one (1%) RTOG grade 3 rectal complication, and also noted the duration of urinary side-effects to last approximately six months. Symptoms were statistically correlated to the dose of Cs-131 delivered.

Related posts

Scroll to top